FibroBiologics and Charles River have announced the completion of FibroBiologics’ master cell bank for a product that will be evaluated for the treatment of diabetic foot ulcers and other ...

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 ...

After three years of development, a smart insole designed by researchers at the University of Malta is showing promising ...

The future of wearable foot technology is promising, however. Devices are becoming smaller, more affordable and easier to use. Innovations like 3D printing now enable customised smart insoles that ...

Our Phase 1/2a clinical trial has demonstrated that the use of this stem cell population in humans is safe and effective in treating hard to heal diabetic foot ulcers." "We are extremely pleased ...

Diabetic foot screening intervals could be extended beyond 1 year for patients at very low risk for diabetic foot complications.

Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product ...

Podimetrics, a leading company specializing in complex diabetes solutions, has announced a new partnership with HealthMed, a ...

Diabetic foot ulcers (DFU) are common complications of diabetes. Also known as Diabetic Foot Disease (DFD) or Diabetic Foot Syndrome (DFS), this condition is usually caused due to neuropathy ...

Celularity (CELU) welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date ...